Maybe you've reached the number you were hoping for. The clothes fit differently, your labs look better, and somewhere in the back of your mind a reasonable question has started to form: do I have to stay on this forever?
It's one of the most common things people wonder once a GLP-1 medication has done what they hoped it would. And it deserves a real answer rather than a slogan.
The honest version starts with something that isn't about willpower at all. What happens to your weight after you stop is, more than anything, a matter of biology, and the research on it is clearer than most people expect.
Your Body Defends a Set Point
Weight isn't only the sum of daily choices. Your body regulates it actively, through hormones that govern hunger and fullness, and it tends to defend a higher weight once it has lived there for a while. That's part of why losing weight and keeping it off through effort alone is so hard for so many people, and why it has almost nothing to do with discipline.
GLP-1 medications work, in part, by turning down those hunger signals. Appetite quiets, meals end sooner, and the body stops fighting quite so hard. When the medication stops, though, the signaling largely returns to where it was. The biology that was being held in check comes back online. Hunger returns, portions drift back toward where they used to sit, and the scale often follows. None of that requires a lapse in effort. It's simply the setting the body was always inclined to return to.
This is worth saying plainly, because so many people carry quiet shame about it. Regaining weight after stopping is not a personal failure. It's a predictable physiological response, and understanding it is the difference between feeling blindsided and making a plan.
What the Trials Actually Showed
Two large studies put real numbers on this, using two different medications.
In the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, researchers followed 327 participants after semaglutide was stopped. At the end of treatment, they had lost an average of 17.3% of their body weight. One year after stopping, that figure had slipped to 5.6%. Put another way, they regained about two-thirds of what they had lost, roughly 11.6 percentage points.
The pattern held for a different molecule too. In SURMOUNT-4, published in JAMA in 2024, adults took tirzepatide during an initial phase and lost an average of 20.9% of their weight. The 670 who reached that point were then randomized: those switched to a placebo regained about 14% of their weight over the following year, while those who kept taking the medication lost a further 5.5%. The gap between staying on and stopping came to roughly 19 percentage points.
Two medications, two trials, the same underlying lesson: in the populations studied, the benefit depended heavily on continued treatment. The medication doesn't rewrite the set point. It holds it, for as long as it's in the picture.
Why This Reframes the Medication
Here's the more useful way to hold all of this. Obesity behaves like a chronic condition, closer to high blood pressure than to a bout of the flu. We don't expect blood pressure to stay low for years after someone stops their medication, and we don't read its return as a failure of character. A GLP-1 works along the same lines.
That doesn't mean everyone has to stay on one indefinitely. Some people taper, some pause and restart, some continue, and the right path depends on your goals, your health, and how your own body responds. What the data argue against is treating the medication as a short sprint toward a finish line, after which everything simply stays put.
The decision to continue, adjust, or step away is a genuinely medical one. It's best made with a physician who is watching the whole picture with you, rather than settled by whether a refill happens to go through.
What This Means for You
Picture someone here in Lubbock who reached her goal over the past year and is starting to think about what comes next. In a hurried system, that conversation might never really happen. She'd get a refill or she wouldn't, and she might be caught off guard by what her body does without the medication.
In a practice built around time, it's a planned discussion instead. Dr. Sima Shahbandar can look at your labs, your muscle mass, your habits, and your history, and help you decide whether to maintain, taper slowly, or reinforce the foundation, protein, strength training, and sleep, that gives you the best chance of holding your progress. Protecting the muscle you built along the way matters here as well, and it's part of the same long view. It's the kind of ongoing care that a quick online prescription simply isn't set up to provide.
None of this is about staying on a medication forever. It's about not being left to guess.
Let's Talk About the Long Arc
If you're weighing what comes after a GLP-1, or you're just starting and want to think past the first few months, that's exactly the kind of conversation we make room for in our approach to medically supervised weight loss. There's no single right answer, and no pressure toward one. You can reach us through our contact page or call (806) 778-4395, and we'll take the time to map out a plan that fits your body and your life. The goal was never only the number. It was keeping the health you worked for.
Sources
- Among 327 participants, mean weight loss of 17.3% at the end of treatment fell to a net 5.6% one year after withdrawal, a regain of 11.6 percentage points, which the authors describe as two-thirds of the prior weight loss: Wilding JPH, et al., "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension," Diabetes, Obesity and Metabolism, 2022, full text via UCL Discovery
- After a mean 20.9% weight reduction during the lead-in, the 670 randomized participants changed by 14.0% on placebo against negative 5.5% on continued tirzepatide, a difference of 19.4 percentage points: Aronne LJ, et al., "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial," JAMA, 2024;331(1):38-48, journal article
This article is for general educational purposes and is not medical advice, diagnosis, or treatment, and it does not create a physician-patient relationship. Individual results vary, and no outcome is guaranteed. Treatment decisions should be made with a qualified physician who knows your full medical history. Omri Med is a private-pay concierge practice; membership is limited and does not replace health insurance.